Clinical trials: Clinically Significant Portal Hypertension
Liver Cirrhosis, Portal Hypertension.
Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension
In the genesis and maintenance of PH associated with liver cirrhosis are two mechanisms that act synergistically. The first is an increase in hepatic vascular resistance, due in part to the disruption of liver structure inherent…
- Trial name
- SIMBETA (NCT01282385)
- Testing
- Simvastatin
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Portal Hypertension Related to Cirrhosis, Esophageal Varices
2D-shear Wave Spleen Elastography in Clinically Significant Portal Hypertension and High-risk Varices
The primary objective of this study is to evaluate the role of spleen shear wave elastography (SWE-SSM) for ruling in and ruling out clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic…
- Trial name
- NCT07122622
- Where
- Italy
- Volunteers
- 450 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Clinically Significant Portal Hypertension
The Impact of Carvedilol Posology on Clinically Significant Portal Hypertension
Carvedilol has emerged as the preferred non-selective β-blocker (NSBB) for treating portal hypertension. However, there is still a debate in dosing regimen, specially regarding dose interval, with a potential lower bioavalability…
- Trial name
- NCT06015373
- Testing
- supress the night dose of carvedilol
- Where
- Portugal
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Centro Hospitalar De São João, E.P.E.
Liver Transplant With Clinically Significant Portal Hypertension
Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.
This study is a 5 day, single-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of Somatostatin used as inflow modulator in liver transplantation.
- Trial name
- NCT01290172
- Testing
- Administration of Somatostatin
- Where
- Belgium
- Volunteers
- 33 people
- Sponsor
- University Hospital, Ghent
Portal Hypertension, Spleen Disease
Liver Cirrhosis Complicated by Clinically Significant Portal Hypertension
Portal hypertension is a major complication of cirrhosis. HVPG is the diagnostic gold standard but is invasive. Non-invasive tools such as spleen stiffness measurement (SSM) and CEUS show promise for assessing CSPH, though they…
- Conditions
- Portal Hypertension, Spleen Disease, Cirrhosis
- Trial name
- CIRCE (NCT07365709)
- Testing
- SonoVue
- Volunteers
- 107 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hypertension, Portal
Radiomics Signature of Hepatic Venous Pressure Gradient (rHVPG) With CT Angiography (CHESS1701)
This is a prospective, multi-center diagnostic trial conducted at 5 high-volume liver centers in China designed to determine the diagnostic performance of radiomics-based hepatic venous pressure gradient (rHVPG) (investigational…
- Trial name
- rHVPG (NCT03138915)
- Testing
- HVPG measurement, CTA
- Where
- 6 sites in China
- Volunteers
- 385 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Cirrhosis, Portal Hypertension
Value of Von Willebrand Factor in Portal Hypertension
In patients with liver cirrhosis elevated levels of von Willebrand factor antigen (vWF-Ag) are found frequently but the clinical significance is unclear.
- Trial name
- NCT01358123
- Where
- Austria
- Volunteers
- 300 people
- Sponsor
- Medical University of Vienna
Hepatocellular Carcinoma With CSPH
Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma
The aim of this study is to compare the operative complication and short-/long-term therapeutic effects of percutaneous local ablative therapy (PLAT) versus surgical resection(SR) on small hepatocellular carcinoma(HCC) patients…
- Trial name
- NCT01860222
- Testing
- SR, PLAT
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hypertension, Portal
Virtual Hepatic Venous Pressure Gradient (vHVPG) With CT Angiography (CHESS1601)
This is a prospective, multi-center trial conducted at 1 Guangzhou and 2 Beijing centers designed to determine the diagnostic performance of virtual hepatic venous pressure gradient (vHVPG) (investigational technology) by…
- Trial name
- vHVPG (NCT02842697)
- Testing
- HVPG measurement, CTA, Doppler ultrasound
- Where
- 3 sites in China
- Volunteers
- 102 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatic Carcinoma
Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
Clinically significant portal hypertension limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis.
- Trial name
- NCT06245798
- Testing
- transarterial chemoembolisation
- Where
- 2 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Tang-Du Hospital
Asymptomatic Cirrhosis, Clinically Significant Portal Hypertension
Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial
Decompensation of cirrhosis is a turning point in cirrhosis course, as associated with a marked decrease in life expectancy. Thus, prevention of decompensation is crucial.
- Trial name
- CARVECIR (NCT06263816)
- Testing
- Experimental group: Patients will be treated with carvedilol.
- Where
- 24 sites in France
- Volunteers
- 290 people
- Sponsor
- University Hospital, Tours